secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-08-17T10:04:44+00:00
Accession:  0001683168-26-006501
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Valion Bio terminates CEO, appoints COO, secures $1.5M funding from 3i
----------------------------------------------------------------------

- CEO Michael K. Handley terminated effective Aug 16, 2026; Lisa Wolf appointed COO, remains CFO.
- Letter Agreement with 3i, LP: $1.5M for 1,500 Series B Preferred at $1,000/share plus warrants.
- Second closing of $1.5M for another 1,500 shares if definitive side letter executed by Aug 24, 2026.
- Royalty Agreement: 5% of Velocity Bioworks gross revenue for 10 years to 3i and other purchasers.
- Stockholders approved reverse stock split (1:5 to 1:50) at special meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826006501/0001683168-26-006501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826006501/valion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-006501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer